Imavir Skin Cream is indicated for the treatment of Herpes Simplex virus infections of the skin including initial and recurrent genital herpes and herpes labialis. Route of administration: topical. Do not use in eyes.

Adults and Children: Imavir Cream should be applied five times daily at approximately four hourly intervals, omitting the night time application. Imavir Cream should be applied to the lesions or impending lesions as soon as possible, preferably during the early stages (prodrome or erythema). Treatment can also be started during the later (papule or blister) stages. Treatment should be continued for at least 4 days for herpes labialis and for 5 days for genital herpes. If healing has not occurred then treatment may be continued for up to an additional 5 days. Use in the elderly: No special comment

Imavir Skin Cream is not recommended for application to mucous membranes such as in the mouth, eye or vagina, as it may be irritant. Particular care should be taken to avoid accidental introduction into the eye.

In severely immunocompromised patients (eg AIDS patients or bone marrow transplant recipients) oral Imavir dosing should be considered. Such patients should be encouraged to consult a physician concerning the treatment of any infection. The excipient propylene glycol can cause skin irritations and the excipient cetyl alcohol can cause local skin reactions (e.g. contact dermatitis). Imavir Cream contains a specially formulated base and should not be diluted or used as a base for the incorporation of other medicaments.

No clinically significant interactions have been identified.

Pregnancy: A post-marketing aciclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of Imavir. The registry findings have not shown an increase in the number of birth defects amongst acyclovir exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. Systemic administration of acyclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rabbits, rats or mice. In a non-standard test in rats, foetal abnormalities were observed but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain. The use of Imavir Cream should be considered only when the potential benefits outweigh the possibility of unknown risks however the systemic exposure to aciclovir from topical application of Imavir Cream is very low. Teratogenicity: Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure to indicate little relevance to clinical use (see section 5.3) Breast-feeding: Limited human data show that the drug does pass into breast milk following systemic administration. However, the dosage received by a nursing infant following maternal use of Imavir Cream would be insignificant. Fertility: There is no information on the effect of aciclovir on human female fertility. In a study of 20 male patients with normal sperm count, oral aciclovir administered at doses of up to 1g per day for up to six months has been shown to have no clinically significant effect on sperm count, motility or morphology. See Clinical Studies in section 5.2

NA

The following convention has been used for the classification of undesirable effects in terms of frequency: very common ≥1/10, common ≥1/100 and <1/10, uncommon ≥1/1000 and <1/100, rare ≥1/10,000 and <1/1000, very rare <1/10,000. Immune system disorders: Very rare • Immediate hypersensitivity reactions including angioedema and urticaria. Skin and subcutaneous tissue disorders: Uncommon • Transient burning or stinging following application of Imavir Cream • Mild drying or flaking of the skin • Itching Rare • Erythema • Contact dermatitis following application. Where sensitivity tests have been conducted, the reactive substances have most often been shown to be components of the cream rather than aciclovir
If you experience any side effect not mentioned above please report it to the National
Pharmacovigilance and Drug Safety Center:
- Saudi Arabia:
- The National Pharmacovigilance and Drug Safety Center (NPC)
• Fax:+966-11-205-7662
• Call NPC at +966-11-2038222 , Ext:2317-2356-2353-2354-2334-2340
• Toll free phone:8002490000
• E-mail: npc.drug@sfda.gov.sa
• Website: www.sfda.gov.sa/npc

No untoward effects would be expected if the entire contents of a 10 gram tube of Imavir Cream containing 500 mg of aciclovir were ingested orally. However the accidental, repeated overdose of oral aciclovir, over several days has resulted in gastrointestinal effects (nausea and vomiting) and neurological effects (headache and confusion). Aciclovir is dialysable by haemodialysis.

Aciclovir is an antiviral agent which is highly active in vitro against herpes simplex virus (HSV) types I and II and varicella zoster virus. Toxicity to mammalian host cells is low. Aciclovir is phosphorylated after entry into herpes infected cells to the active compound aciclovir triphosphate. The first step in this process is dependent on the presence of the HSV-coded thymidine kinase. Aciclovir triphosphate acts as an inhibitor of, and substrate for, the herpes-specified DNA polymerase, preventing further viral DNA synthesis without affecting normal cellular processes In two large, double blind, randomised clinical studies involving 1,385 subjects treated over 4 days for recurrent herpes labialis, Imavir Cream 5% was compared to vehicle cream. In these studies, time from start of treatment to healing was 4.6 days using Imavir Cream and 5.0 days using vehicle cream (p<0.001). Duration of pain was 3.0 days after start of treatment in the Imavir Cream group and 3.4 days in the vehicle group (p=0.002). Overall, approximately 60% of patients started treatment at an early lesion stage (prodrome or erythema) and 40% at a late stage (papule or blister). The results were similar in both groups of patients.

Pharmacology studies have shown only minimal systemic absorption of aciclovir following repeated topical administration of Imavir Cream.

The results of a wide range of mutagenicity tests in vitro and in vivo indicate that aciclovir does not pose a genetic risk to man. Aciclovir was not found to be carcinogenic in long term studies in the rat and the mouse. Largely reversible adverse effects on spermatogenesis in association with overall toxicity in rats and dogs have been reported only at doses of aciclovir greatly in excess of those employed therapeutically. Two generation studies in mice did not reveal any effect of orally administered aciclovir on fertility. Systemic administration of aciclovir in internationally accepted standard tests did not produce embryotoxic or teratogenic effects in rats, rabbits or mice In a non-standard test in rats, foetal abnormalities were observed, but only following such high subcutaneous doses that maternal toxicity was produced. The clinical relevance of these findings is uncertain.

Tefose 63
Paraffin Oil
Labrafil
Propylene Glycol
Benzoic Acid
Highly Purified Water

None known.

- Discard contents four weeks after opening. - Store below 30°C. Don’t refrigerate.

Imavir Skin Cream is stored in Aluminum tube - collapsible aluminium tubes with plastic screw caps. Pack sizes: 5 gm., 15 gm..

For external use only.